KFF

Federal data reports that U.S. prescription drug prices fell 3.1% from a year ago, marking the steepest year-over-year drop since 1963. Although the White House credits these price declines to Trump's drug deals, experts note that other factors are potentially more significant contributors. These complex factors include Medicare negotiations allowed by the Inflation Reduction Act and increased market competition from generic or biosimilar drugs.

Recent federal data shows that U.S. prescription drug prices declined 3.1% from a year ago, the steepest drop since 1963. While Donald Trump has taken credit for these drops through “most favored nation” deals, experts suggest other factors are equally significant. These contributors include competition from generic and biosimilar products, as well as policy changes like the Inflation Reduction Act's allowance for Medicare to negotiate drug costs.

U.S. prescription drug prices declined 3.1% from a year ago, marking the steepest drop since 1963. Although President Donald Trump claims credit via 'most favored nation' deals, experts note the price reduction is complex. Contributing factors include Medicare's ability to negotiate costs through policies like the Inflation Reduction Act, and market competition fueled by generic and biosimilar drugs.

Facing rising healthcare costs projected to increase 6.7% in 2026, employers are pressured to either absorb these costs or pass higher out-of-pocket expenses to workers. The article advises that before doing so, companies should ask healthcare providers about operational efficiency, suggesting that determining if existing capacity can be better utilized can prevent the need for expensive new physical expansions.

ACA premiums are rising sharply, with a proposed 15% median increase for 2027, impacting individuals like Donna Rowell, who pays $530 monthly. A 2021 policy decision to stop funding low-cost ACA premiums in 2025 contributed to the spike, leading 14% of Tennesseans to drop coverage. Rhonda Clark, who relies on ACA for care, found her plan insufficient and unaffordable, now paying out-of-pocket for medical expenses.

The article explains that Medicare beneficiaries can switch supplement plans, detailing the 10 available Medigap options (A, B, C, etc.) and emphasizing Plan G as a popular choice. It highlights standardized benefits across plans, cost variations by state and insurer, and comparisons between Medigap and Medicare Advantage plans.

The article discusses how AI chatbots may exacerbate anxiety by reinforcing avoidant coping behaviors, citing a study by Stanford researchers Elias Aboujaoude and Ashleigh Golden. A KFF poll indicates one in six adults use chatbots for mental-health advice, raising concerns about technology worsening anxiety symptoms.

The Trump administration is ending a Medicare drug subsidy program initiated by the Biden administration in 2024, leading to potential 2027 premium increases for 25 million Medicare Part D beneficiaries. Federal officials claim the impact will be minimal, with most seeing less than a $10-per-month increase, while Democrats criticize the move as increasing healthcare costs for seniors.

The Trump administration is ending a Medicare drug subsidy program that lowered prescription drug costs for 25 million seniors, leading to potential higher monthly premiums in 2027. The program, initially implemented by the Biden administration in 2024, was a response to the 2022 Inflation Reduction Act. Democrats criticized the decision as increasing costs for seniors, while CMS claims the impact will be minimal, with most beneficiaries seeing less than a $10 monthly increase.

Obamacare enrollment declined in 49 states following the expiration of federal subsidies, with New Mexico being the sole exception after using state funds to replace the aid. The Trump administration attributed part of the decline to fraudulent enrollments, while KFF linked it to the loss of pandemic-era subsidies.

Obamacare enrollment declined in 49 states due to expired federal subsidies, with Virginia experiencing an 8% drop. New Mexico was the only state to see an increase in enrollment after using state funds to replace the expired subsidies. KFF reported average enrollment drops of 6% in states with state-run exchanges and 15% in federal marketplace states.

Obamacare enrollment declined in 49 states due to expired federal subsidies, with New Mexico being the only exception where state funds replaced the aid. The Trump administration attributed past enrollment growth to fraud, while KFF linked the recent drop to subsidy expiration.

Obamacare enrollment declined in 49 states following the expiration of federal subsidies, with New Mexico being the only state to fully replace the aid using state funds. The Trump administration attributed prior enrollment growth to fraudulent activity, while KFF linked the decline to subsidy expiration.

Obamacare enrollment declined in 49 states due to expired federal subsidies, with New Mexico being the only exception where enrollment increased after using state funds to replace subsidies. The Trump administration attributed past enrollment growth to fraud, while KFF linked the recent drop to subsidy expiration.

Enrollment in Obamacare plans declined in 49 states due to expired federal subsidies, with Louisiana and Mississippi among the hardest-hit states at 26% drops. New Mexico was the only state to see an increase in enrollment after using state funds to replace expired subsidies.

The $50 billion Rural Health Transformation program, part of the One Big Beautiful Bill Act, aims to expand rural healthcare access. States competed for first-year funding allocations, with New Jersey receiving $147 million and Texas $281 million. Public documents for each state are available for review.

The article argues that the MAHA movement, often dismissed as anti-vaccine and anti-science, represents broader public concerns about environmental pollutants, healthcare costs, and corporate influence in health policy. While MAHA includes a vocal anti-vaccine faction, polling indicates most supporters prioritize healthcare affordability and chemical additives, with only a small fraction citing vaccines as their main concern.

North Carolina ranks poorly in healthcare affordability, prompting the formation of the North Carolina Health Care Affordability Commission to address rising costs. Experts highlighted national challenges, including high U.S. healthcare spending and medical debt, with Indiana's cost-control measures cited as a potential model.

A KFF poll shows most Americans doubt Medicaid recipients are the main source of fraud, viewing allegations as political maneuvering. The poll highlights concerns about healthcare affordability over Medicaid fraud, as Trump-era Medicaid cuts and tax policies face scrutiny.

A KFF poll shows most Americans do not believe Medicaid recipients are the primary source of fraud and view the anti-fraud push as political. The poll highlights greater concern about taxes than Medicaid fraud, while a Senate bill proposes cutting Medicaid funding for clinics providing abortions. President Trump's 'Big Beautiful Bill' reduced Medicaid by $1 trillion over 10 years, contributing to coverage drops in states like Ohio.

Ohio Auditor Keith Faber made statements implying support for ending parts of Ohio Medicaid, though his campaign clarified he supports lawful use of Medicaid funds. The program covers over 3 million Ohioans and costs $40 billion annually. President Trump previously questioned federal Medicaid funding, and a Democratic candidate accused Republicans of exaggerating provider fraud to justify cutting the program.

Trust in the FDA has dropped from 75% to 50% in two years, driven by public concerns about political interference in decision-making. HHS Secretary Robert F. Kennedy Jr. has publicly criticized the FDA as 'corrupt' and pressured it to loosen oversight of therapies, conflicting with scientific recommendations.

Obamacare premiums are projected to rise by a median of 14% in 2027, with insurers citing expired subsidies, rising healthcare costs, and federal regulation changes. A report by the Peterson Center on Healthcare and KFF analyzed proposed rate increases from 77 insurers across 16 states, showing most plan hikes between 10-20%, with none proposing decreases.

Affordable Care Act Marketplace insurers are proposing a median premium increase of 14% for 2027, marking the second consecutive year of double-digit hikes. The expiration of enhanced subsidies, rising healthcare costs, and regulatory changes are cited as reasons, while enrollments in Marketplace plans dropped by 2.6 million in February compared to the prior year.

Obamacare premiums are projected to rise by 14% in 2027, with insurers citing rising healthcare costs, federal regulatory changes, and expired pandemic-era subsidies as key factors. Middle-income Americans without subsidies will face significant cost increases, while federal lawmakers have proposed healthcare reforms but lack legislative support.

Obamacare premiums are projected to rise by a median of 14% in 2027, with 77 insurers across 16 states and Washington, D.C., proposing increases. The hikes follow the expiration of enhanced subsidies and rising healthcare costs, leading to fewer healthier enrollees and higher costs for those with incomes above 400% of the federal poverty level.

Obamacare premiums are projected to rise by 14% in 2027, with insurers citing rising healthcare costs and expired subsidies as key factors. The analysis of 77 insurers across 16 states and Washington, D.C., shows most proposing increases between 10-20%, while 20 insurers seek hikes above 20%. Marketplace enrollments have dropped by 2.6 million since February 2023.

Obamacare premiums are projected to rise 14% in 2027, driven by higher healthcare costs, federal regulatory changes, and expired subsidies. Middle-income Americans without subsidies face significant cost increases, as insurers cite a shrinking, sicker insurance pool and inflation.

Health insurance premiums for Affordable Care Act Marketplace plans are projected to rise by a median of 14% in 2027, marking the second consecutive year of double-digit increases. Insurers attribute the hikes to expired subsidies, rising healthcare costs, and federal regulatory changes, while enrollments in Marketplace plans have dropped by 2.6 million since February 2023.

Health insurance premiums for Affordable Care Act Marketplace plans are projected to rise by a median of 14% in 2027, with no proposed decreases. Insurers attribute the increases to rising healthcare costs, expired subsidies, and regulatory changes. The analysis by the Peterson Center on Healthcare and KFF reviewed 77 insurers across 16 states and Washington, D.C.

Obamacare premiums are projected to rise by a median of 14% in 2027, with insurers citing rising healthcare costs and expired subsidies as key factors. A report by the Peterson Center on Healthcare and KFF found 77 insurers across 16 states and Washington, D.C., proposing increases, with none requesting decreases. Marketplace enrollments have dropped by 2.6 million since last year.

Obamacare premiums are projected to rise by 14% in 2027, with insurers citing rising healthcare costs and expired subsidies as key factors. A report by the Peterson Center on Healthcare and KFF found 77 insurers across 16 states propose median increases between 10% and 20%, marking the second consecutive year of double-digit hikes. Marketplace enrollments dropped by 2.6 million in February compared to the prior year.

Insurers in the Affordable Care Act (ACA) program propose a median 14% premium increase for 2027, citing rising healthcare costs, regulatory changes, and expired pandemic subsidies. Middle-class enrollees without subsidies will face significant cost increases, adding to a 20% median rise in 2026.

ObamaCare premiums could increase by 14% next year based on insurers' initial filings, according to KFF analysis. This would represent the second consecutive year of double-digit premium hikes, leading to higher costs for customers.

A new analysis by KFF reveals that Affordable Care Act (Obamacare) insurers are proposing a 14% median premium increase for 2027, following a 20% rise in 2026. Insurers attribute the hikes to rising healthcare costs, expired federal subsidies, and a sicker, smaller enrollee pool, disproportionately affecting middle-class individuals.

A new analysis by KFF reveals that Affordable Care Act insurers are proposing a 14% median premium increase for 2027, driven by rising healthcare costs, regulatory changes, and expired pandemic-era subsidies. The ACA marketplace has shrunk by over 2.5 million enrollees since the subsidies ended, contributing to higher costs for middle-class enrollees without subsidies.

Obamacare premiums are set to rise by a median of 14% in 2027, the second consecutive year of double-digit increases, driven by rising healthcare costs and expired subsidies. Higher out-of-pocket costs are causing some healthier enrollees to drop coverage, worsening the affordability crisis and shrinking the insurance market, which now has 19.2 million enrollees, down 3 million from the previous year.

Affordable Care Act insurers are proposing a median 14% premium increase for 2027 due to rising medical costs and policy changes, with enrollment declining by 3 million since February 2023. The expiration of enhanced subsidies under former President Trump and increased demand for costly treatments like GLP-1 weight loss drugs are cited as key factors.

Federal data shows a significant decline in Affordable Care Act (ACA) enrollments across many states, with Ohio and Oklahoma losing nearly one-third of enrollees. The drop, attributed to expired enhanced subsidies and stricter enrollment rules, resulted in 2.6 million fewer Americans with ACA coverage in February 2023 compared to the prior year.

Federal data shows a significant decline in Affordable Care Act (ACA) enrollments across many states, with Ohio and Oklahoma each losing over 32% of enrollees since January 2023, attributed to the expiration of enhanced subsidies and rising premiums. The data reveals 2.6 million fewer Americans with ACA plans in February 2023 compared to the same period the previous year.